Replies to post #146339 on Biotech Values

[DewDiligence]

Feuerstein’s take on DNDN:

http://www.thestreet.com/story/11645155/2/dendreons-provenge-problems-reach-terminal-stage.html

Pretty good analysis, IMO. Feuerstein might have added that closing the NJ plant will increase the operating costs at the two remaining plants (in GA and CA) and make the company’s operating margin even more negative than it was before.